Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History CCCC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics CCCC

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

C4 Therapeutics Inc

CCCC
Current price
2.18 USD +0.21 USD (+10.66%)
Last closed 2.02 USD
ISIN US12529R1077
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 154 795 488 USD
Yield for 12 month -65.12 %
1Y
3Y
5Y
10Y
15Y
CCCC
21.11.2021 - 28.11.2021

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BRAF V600 mutant that is in Phase 1/2 clinical trials to treat melanoma, colorectal cancer, and other solid malignancies; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor with an L858R mutation in non-small cell lung cancer. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; Merck KGaA; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. Address: 490 Arsenal Way, Watertown, MA, United States, 02472

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

15.80 USD

P/E Ratio

Dividend Yield

Financials CCCC

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures CCCC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+35 584 000 USD

Last Year

+20 756 000 USD

Current Quarter

+7 238 000 USD

Last Quarter

+5 177 000 USD

Current Year

+35 584 000 USD

Last Year

-96 950 000 USD

Current Quarter

+7 238 000 USD

Last Quarter

+3 411 000 USD
EBITDA -114 733 000 USD
Operating Margin TTM -402.93 %
Price to Earnings
Return On Assets TTM -20.30 %
PEG Ratio
Return On Equity TTM -45.55 %
Wall Street Target Price 15.80 USD
Revenue TTM 39 783 000 USD
Book Value 2.75 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 138.20 %
Dividend Yield
Gross Profit TTM -75 393 000 USD
Earnings per share -1.48 USD
Diluted Eps TTM -1.48 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -259.60 %

Stock Valuation CCCC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 0.46
Price Sales TTM 3.89
Enterprise Value EBITDA -0.42
Price Book MRQ 0.87

Technical Indicators CCCC

For 52 Weeks

1.09 USD 7.36 USD
50 Day MA 1.55 USD
Shares Short Prior Month 6 375 598
200 Day MA 3.17 USD
Short Ratio 6.29
Shares Short 4 962 321
Short Percent 9.70 %